-
公开(公告)号：US20190112306A1
公开(公告)日：2019-04-18
申请号：US16087320
申请日：2017-03-20
Inventor： Niall Andrew ANDERSON , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , Seble LEMMA , John Martin PRITCHARD , Panayiotis Alexandrou PROCOPIOU , Steven Leslie SOLLIS
IPC: C07D471/04 , A61P11/00
Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having αvβ6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an αvβ6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.
-
公开(公告)号：US20190040051A1
公开(公告)日：2019-02-07
申请号：US16073355
申请日：2017-02-10
Inventor： Niall Andrew ANDERSON , Nicholas Paul BARTON , Sebastien Andre CAMPOS , Edward Paul CANNONS , Anthony William James COOPER , Kenneth David DOWN , Kevin James DOYLE , Julie Nicole HAMBLIN , Graham George Adam INGLIS , Armelle LE GALL , Vipulkumar Kantibhai PATEL , Simon PEACE , Andrew SHARPE , Gemma Victoria WHITE
CPC classification number: C07D413/14 , A61P11/06 , A61P15/08 , A61P25/24 , A61P25/28 , A61P37/08 , C07D213/76
Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
-
公开(公告)号：US20180134665A1
公开(公告)日：2018-05-17
申请号：US15575235
申请日：2016-05-19
Inventor： Niall Andrew ANDERSON , Deepak BANDYOPADHYAY , Alain Claude-Marie DAUGAN , Frederic G. DONCHE , Patrick M. EIDAM , Nicolas Eric FAUCHER , Nicolas S. GEORGE , Philip Anthony HARRIS , Jae U. JEONG , Bryan W. KING , Clark A. SEHON , Gemma Victoria WHITE , David Duff WISNOSKI
IPC: C07D231/06 , C07D401/14 , A61K31/506 , A61K31/4545 , C07D405/14 , A61K31/454 , A61K31/415 , C07D401/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/04 , A61K31/422 , C07D405/04 , C07D413/14 , A61K31/5377 , C07D417/14 , C07D409/14 , C07D409/06 , A61P21/00
CPC classification number: C07D231/06 , A61K31/415 , A61K31/422 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61P21/00 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04
Abstract: Disclosed are compounds having the formula (I): wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
-
公开(公告)号：US20200165205A1
公开(公告)日：2020-05-28
申请号：US16778206
申请日：2020-01-31
Inventor： Niall Andrew ANDERSON , Deepak BANDYOPADHYAY , Alain Claude-Marie DAUGAN , Frederic G. DONCHE , Patrick M. EIDAM , Nicolas Eric FAUCHER , Nicolas S. GEORGE , Philip Anthony HARRIS , Jae U. JEONG , Bryan W. KING , Clark A. SEHON , Gemma Victoria WHITE , David Duff WISNOSKI
IPC: C07D231/06 , C07D413/04 , C07D409/06 , C07D403/06 , A61K31/5377 , A61K31/506 , A61K31/4545 , A61K31/454 , A61K31/422 , A61K31/415 , A61P21/00 , C07D417/14 , C07D409/14 , C07D405/06 , C07D405/04 , C07D401/06 , C07D401/04 , C07D413/14 , C07D405/14 , C07D401/14 , C07D487/04 , C07D403/04
Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
-
5.发明申请公开(公告)号：US20190048005A1
公开(公告)日：2019-02-14
申请号：US16165506
申请日：2018-10-19
Inventor： Niall Andrew ANDERSON , Ian Baxter CAMPBELL , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , Seble LEMMA , Simon John Fawcett MACDONALD , John Martin PRITCHARD , Panayiotis Alexandrou PROCOPIOU
IPC: C07D471/04 , C07B59/00
CPC classification number: C07D471/04 , C07B59/002 , C07B2200/05
Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
-
Patent Agency Ranking
公开(公告)号：US20200071311A1
公开(公告)日：2020-03-05
申请号：US16572917
申请日：2019-09-17
Inventor： Niall Andrew ANDERSON , Nicholas Paul BARTON , Sebastien Andre CAMPOS , Edward Paul CANNONS , Anthony William James COOPER , Kenneth David DOWN , Kevin James DOYLE , Julie Nicole HAMBLIN , Graham George Adam INGLIS , Armelle LE GALL , Vipulkumar Kantibhai PATEL , Simon PEACE , Andrew SHARPE , Gemma Victoria WHITE
IPC: C07D413/14 , A61P15/08 , A61P25/24 , A61P37/08 , A61P11/06 , A61P25/28 , C07D213/76
Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
-
7.发明申请公开(公告)号：US20170291899A1
公开(公告)日：2017-10-12
申请号：US15514416
申请日：2015-09-22
Inventor： Niall Andrew ANDERSON , Ian Baxter CAMPBELL , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , Seble LEMMA , Simon John Fawcett MACDONALD , John Martin PRITCHARD , Panayiotis Alexandrou PROCOPIOU
IPC: C07D471/04 , C07B59/00
CPC classification number: C07D471/04 , C07B59/002 , C07B2200/05
Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, Ri does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
-
公开(公告)号：US20170290818A1
公开(公告)日：2017-10-12
申请号：US15514414
申请日：2015-09-22
Inventor： Niall Andrew ANDERSON , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , Seble LEMMA , Simon John Fawcett MACDONALD , John Martin PRITCHARD , Panayiotis Alexandrou PROCOPIOU , Stephen SWANSON
IPC: A61K31/4375 , C07D207/04 , C07D471/04
CPC classification number: A61K31/4375 , C07D207/04 , C07D471/04
Abstract: A compound according to formula (I) wherein R1 is hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20210206758A1
公开(公告)日：2021-07-08
申请号：US16087349
申请日：2017-03-20
Inventor： Niall Andrew ANDERSON , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , Seble LEMMA , John Martin PRITCHARD , Panayiotis Alexandrou PROCOPIOU , Joanna Mary REDMOND , Steven Leslie SOLLIS
IPC: C07D471/04
Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having αvβ6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in therapy, including in the treatment of a disease or condition for which an αvβ6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.
-
公开(公告)号：US20190275016A1
公开(公告)日：2019-09-12
申请号：US16423455
申请日：2019-05-28
Inventor： Niall Andrew ANDERSON , Matthew Howard James CAMPBELL-CRAWFORD , Ashley Paul HANCOCK , John Martin PRITCHARD , Joanna Mary REDMOND
IPC: A61K31/4375 , C07D471/04
Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.016 seconds)
